New daily pill shows promise for rheumatoid arthritis in early trial

NCT ID NCT07335952

Completed Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested Proximod, a daily pill that calms the immune system, in 179 adults with moderate-to-severe rheumatoid arthritis who had not responded well to standard treatments. Participants took either 5 mg, 10 mg, or a placebo daily for three months, with one month of follow-up. The main goal was to see if Proximod could reduce joint pain and swelling better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proximod (a daily pill that modulates the immune system)
What this could lead to: If it works, this could point toward a new daily treatment option for people with rheumatoid arthritis who haven't responded to standard drugs.
What could go wrong: This is an early Phase 2 trial with only 179 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Chun Li

Beijing, Beijing Municipality, 100044, China
Guixiu Shi

Xiamen, Fujian, 361003, China
Hua Zhang

Zaozhuang, Shandong, 277100, China
Huaxiang Wu

Hangzhou, Zhejiang, 310009, China
Jian Wu

Suzhou, Jiangsu, 215006, China
Jiashun Zeng

Guiyang, Guizhou, 550004, China
Ling Lei

Nanning, Guangxi, 530021, China
Lingli Dong

Wuhan, Hubei, 430030, China
Mei Tian

Zunyi, Guizhou, 563099, China
Mingwei Deng

Guangzhou, Guangdong, China
Qingwen Wang

Shenzhen, Guangdong, 518036, China
Senhua Dai

Pingxiang, Jiangxi, 337055, China
Shulin Song

Yichang, Hubei, 43003, China
Weiqi Min

Heze, Shandong, 274006, China
Wubin Long

Chengdu, Sichuan, 610072, China
Xiaofei Shi

Luoyang, Henan, 471000, China
Xuebinwang

Binzhou, Shandong, 256603, China
Yanmei Wu

Panjin, Liaoning, 124000, China
Yi He

Guangzhou, Guangdong, 510630, China
Zili Fu

Taiyuan, Shanxi, 030001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.